Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Academic papers demonstrate what is initially possible but do not produce commercializable products. At ARPA-H, leadership engaged final users from project inception so market demand existed upon completion, preventing breakthroughs from remaining trapped in originating laboratories.

Related Insights

Academic research often proves a concept once, sufficient for publication. However, creating a commercially viable technology requires extensive refinement to ensure it's consistent and repeatable across different users, labs, and equipment. This gap between a single success and a robust product is the "valley of death" for university spinouts.

Corporate labs frequently fizzle after three or four years because parent organizations struggle to commercialize experimental outputs. An effective lab requires builders who can simultaneously explore radical technologies at the frontier and collaborate constructively with core business units to turn apparent 'toys' into mainstream products.

A persistent gap exists where academic innovators develop brilliant science but fail to articulate how it becomes a product. Investors can't fund technology 'thrown over the transom'; they need to see a clear Target Product Profile (TPP) and a path to a return on investment, even at the earliest stages.

The transition from academia to entrepreneurship is most successful when the focus shifts from pure science or technology to solving a tangible, pre-existing clinical problem. This ensures market interest, clinical adoption, and ultimately, patient impact from the outset.

Moving technology from academia to a startup requires a crucial mindset shift. The academic goal of publishing data must be replaced by the industry requirement of extensive validation. For Vivtex, this single piece of advice added years of work but was essential for creating a commercially viable platform.

In AI, low prototyping costs and customer uncertainty make the traditional research-first PM model obsolete. The new approach is to build a prototype quickly, show it to customers to discover possibilities, and then iterate based on their reactions, effectively building the solution before the problem is fully defined.

Scientists moving into entrepreneurship must pivot from promoting their technology's features to listening for customer problems. True product-market fit is often found when the market values an application, like a material being 'animal-free,' that wasn't the primary focus during its scientific development.

For deep tech startups aiming for commercialization, validating market pull isn't a downstream activity—it's a prerequisite. Spending years in a lab without first identifying a specific customer group and the critical goal they are blocked from achieving is an enormous, avoidable risk.

Moving from a science-focused research phase to building physical technology demonstrators is critical. The sooner a deep tech company does this, the faster it uncovers new real-world challenges, creates tangible proof for investors and customers, and fosters a culture of building, not just researching.

Startups born from PhD research often begin with a technology and must then find its most valuable application, the reverse of identifying a market need first. This makes extensive customer discovery critical to validate demand and pivot from the initial academic focus, as Cellino's founder experienced firsthand.

Research Papers Are Mere Starting Guns That Require Upfront End-User Feedback to Scale | RiffOn